vs
Side-by-side financial comparison of DONEGAL GROUP INC (DGICA) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
DONEGAL GROUP INC is the larger business by last-quarter revenue ($236.0M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -3.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -2.2%).
Donegal Group Inc. is a regional US insurance holding company offering personal and commercial property and casualty insurance products. It serves Mid-Atlantic, Midwest, and Southern US customers, delivering tailored coverage for individuals, families, and small to medium businesses.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DGICA vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.0M | $168.4M |
| Net Profit | $11.5M | — |
| Gross Margin | — | — |
| Operating Margin | — | 50.6% |
| Net Margin | 4.9% | — |
| Revenue YoY | -3.7% | 143.7% |
| Net Profit YoY | -54.3% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $236.0M | — | ||
| Q4 25 | $239.8M | $168.4M | ||
| Q3 25 | $245.9M | $87.3M | ||
| Q2 25 | $247.1M | $82.4M | ||
| Q1 25 | $245.2M | $65.0M | ||
| Q4 24 | $250.0M | $69.1M | ||
| Q3 24 | $251.7M | $51.6M | ||
| Q2 24 | $246.8M | $73.8M |
| Q1 26 | $11.5M | — | ||
| Q4 25 | $17.2M | — | ||
| Q3 25 | $20.1M | $-31.3M | ||
| Q2 25 | $16.9M | $-12.7M | ||
| Q1 25 | $25.2M | $-40.5M | ||
| Q4 24 | $24.0M | — | ||
| Q3 24 | $16.8M | $-29.5M | ||
| Q2 24 | $4.2M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 50.6% | ||
| Q3 25 | 10.2% | -11.4% | ||
| Q2 25 | 8.3% | 8.6% | ||
| Q1 25 | 12.7% | -34.0% | ||
| Q4 24 | 11.9% | -6.4% | ||
| Q3 24 | 8.1% | -31.0% | ||
| Q2 24 | 2.0% | 3.5% |
| Q1 26 | 4.9% | — | ||
| Q4 25 | 7.2% | — | ||
| Q3 25 | 8.2% | -35.9% | ||
| Q2 25 | 6.8% | -15.4% | ||
| Q1 25 | 10.3% | -62.2% | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 6.7% | -57.2% | ||
| Q2 24 | 1.7% | -83.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $649.1M | $-302.0M |
| Total Assets | $2.4B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M |
| Q1 26 | $649.1M | — | ||
| Q4 25 | $640.4M | $-302.0M | ||
| Q3 25 | $627.4M | $-451.4M | ||
| Q2 25 | $605.7M | $-433.5M | ||
| Q1 25 | $584.7M | $-426.2M | ||
| Q4 24 | $545.8M | $-388.7M | ||
| Q3 24 | $513.4M | $-370.2M | ||
| Q2 24 | $484.1M | $-344.2M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $465.9M | ||
| Q3 25 | $2.4B | $364.0M | ||
| Q2 25 | $2.4B | $347.1M | ||
| Q1 25 | $2.4B | $324.0M | ||
| Q4 24 | $2.3B | $343.8M | ||
| Q3 24 | $2.3B | $314.1M | ||
| Q2 24 | $2.3B | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $70.2M | $45.2M | ||
| Q3 25 | $22.4M | $-4.3M | ||
| Q2 25 | $12.1M | $-31.4M | ||
| Q1 25 | $25.7M | $-22.6M | ||
| Q4 24 | $67.4M | $-35.0M | ||
| Q3 24 | $12.7M | $-35.3M | ||
| Q2 24 | $21.7M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 2.81× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 5.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DGICA
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
